Stocks and Investing
Stocks and Investing
Fri, April 12, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Bryan Blair Maintained (ZWS) at Buy with Increased Target to $37 on, Apr 12th, 2024
Bryan Blair of Oppenheimer, Maintained "Zurn Elkay Water Solutions Corporation" (ZWS) at Buy with Increased Target from $36 to $37 on, Apr 12th, 2024.
Bryan has made no other calls on ZWS in the last 4 months.
There are 4 other peers that have a rating on ZWS. Out of the 4 peers that are also analyzing ZWS, 3 agree with Bryan's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brett Linzey of "Mizuho" Downgraded from Strong Buy to Hold and Held Target at $34 on, Friday, February 9th, 2024
- Nathan Jones of "Stifel" Downgraded from Strong Buy to Hold and Held Target at $31 on, Tuesday, December 19th, 2023
- David Tarantino of "Keybanc" Downgraded from Buy to Hold on, Wednesday, December 13th, 2023
This is the rating of the analyst that currently disagrees with Bryan
- Andrew Buscaglia of "Exane BNP Paribas" Initiated at Buy and Held Target at $40 on, Tuesday, March 12th, 2024
Contributing Sources